Symptom screening improved symptom scores among children with cancer compared with usual care, two randomized trials showed.

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...

Pulmatrix, Inc. ("Pulmatrix") (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage ...

TeamLease EdTech collaborates with Ministry of Labour & Employment to enhance employability through 200 work-linked degree programs on the National Career Service portal.

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Subscribe here to receive future editions. AstraZeneca said it is doubling down on its investment in its U.S. business, a ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...